Biotechnology

Metagenomi

MSFT

ORCL

SFTBY

OpenAI

SOBKY

AVGO

AMZN

AAPL

603020

DXYZ

NVDA

9984

GOOG

GOOGL

DJTWW

<p><span class="security-tag" type="security-tag" counter_id="ST/NA/OpenAI" name="OpenAI" trend="">$OpenAI(OpenAI.NA)</span> has been extremely busy recently, sometimes engaging in e-commerce, sometimes in social media, and now launching a browser (Dolphin Research's commentary). Emmmm... it seems like half of the Seven Sisters have become rivals. A trending topic every three days, Dolphin Research can hardly keep up. On the surface, OpenAI is thriving, poised to become the next star to reshape humanity's trajectory. But behind the star's glow, Dolphin Research can already sense OpenAI's anxiety. The greater the responsibility, the greater the pressure. Starting from 2026, OpenAI's commercialization capabilities will no longer be just the demands of the initial investors...</p>

Microsoft

Oracle

SoftBank

Trump Media & Tech

Boston Beer

Broadcom

Amazon

Apple

Apple Group

Walmart

Destiny Tech100

NVIDIA

SoftBank Group Corp.

Alphabet - C

Alphabet

Meta Platforms

Trump Media & Tech - CW28

All in the same boat, is OpenAI a divine pearl or a demonic pill?

Chardan Capital Analyst Maintains Buy Rating on Metagenomi

TD Cowen Analyst Reiterates Buy Rating on Metagenomi Stock

Metagenomi released FY2025 Q3 earnings on November 11 After-Market EST, actual revenue USD 8.659 M (forecast USD 7.92 M), actual EPS USD -0.55 (forecast USD -0.584)

Metagenomi released FY2025 9 Months Earnings on November 11 After-Market EST, actual revenue USD 21.3 M, actual EPS USD -1.7581

Metagenomi Switches to AWS Accelerator from Nvidia for Cost-Effective Gene Editing Technology Development

Kapoor Analyzes Healthcare Sector Stocks and Provides Ratings

Metagenomi released FY2025 Q2 earnings on August 12 (EST), actual revenue USD 8.513 M (forecast USD 7.72 M), actual EPS USD -0.5357 (forecast USD -0.6207)

Metagenomi released FY2025 Semi-Annual earnings on August 12 (EST), actual revenue USD 12.64 M, actual EPS USD -1.2118

Metagenomi released FY2025 Q1 earnings on May 13 (EST), actual revenue USD 4.127 M (forecast USD 7.96 M), actual EPS USD -0.6763 (forecast USD -0.5772)

Metagenomi Reports Q1 2025 Financial Results

Metagenomi to Showcase II CRISPR System at ASGCT Annual Meeting

Metagenomi released FY2024 annual earnings on March 17 (EST), actual revenue 52.3 M USD (forecast 51.7 M USD), actual EPS -2.3633 USD (forecast -2.4423 USD)

Metagenomi released FY2024 Q4 earnings on March 17 (EST), actual revenue 9.614 M USD (forecast 9.46 M USD), actual EPS -0.6271 USD (forecast -0.6482 USD)

Metagenomi released FY2024 Q3 earnings on November 13 (EST), actual revenue 11.51 MUSD (forecast 6.786 MUSD), actual EPS -0.5106 USD (forecast -0.7283 USD)

Metagenomi released Q3 2024 earnings on November 13, 2024 (EST), with actual revenue of 42.68M USD and EPS of -1.9935

Analyst Ratings Downgraded for Metagenomi (MGX)

Bragar Eagel & Squire Represents Metagenomi Shareholders in Potential Lawsuit

Law firm Frank R. Cruz is investigating possible federal securities violations by Metagenomi, Inc.

HC Wainwright & Co. Analyst Initiates Coverage on Metagenomi with Buy Rating

JPMorgan Analyst Downgrades Metagenomi Rating from Buy to Neutral, Lowers Price Target to $6

Mega Fortune

Processa Pharmaceuticals

cbdMD

Agape ATP

VYNE Therapeutics

Andersen

Inspirato

Medline Inc.

Creative Global Tech

GCI LIBERTY INC COM USD0.01 SER C SUBS RTS 17/12/2025

ADMA生物制藥

Kiniksa Pharmaceuticals

Stoke Therapeutics

Rigel制藥

OpGen

福泰制藥

再生元制藥

Argenx

阿里拉姆制藥

百濟神州

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio